439 related articles for article (PubMed ID: 25947544)
1. Very early virological failure and drug resistance mutations in a woman on antiretroviral therapy in Eastern Cape, South Africa: a case report.
Sogbanmu OO; Adeniyi OV; Fuentes YO; Ter Goon D
J Med Case Rep; 2015 May; 9():106. PubMed ID: 25947544
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
3. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
[TBL] [Abstract][Full Text] [Related]
4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
5. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
[TBL] [Abstract][Full Text] [Related]
6. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
[TBL] [Abstract][Full Text] [Related]
7. Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic.
Péré H; Charpentier C; Mbelesso P; Dandy M; Matta M; Moussa S; De Dieu Longo J; Grésenguet G; Abraham B; Bélec L
AIDS Res Hum Retroviruses; 2012 Apr; 28(4):315-23. PubMed ID: 21942692
[TBL] [Abstract][Full Text] [Related]
8. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
[TBL] [Abstract][Full Text] [Related]
10. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.
Hamers RL; Sigaloff KC; Wensing AM; Wallis CL; Kityo C; Siwale M; Mandaliya K; Ive P; Botes ME; Wellington M; Osibogun A; Stevens WS; Rinke de Wit TF; Schuurman R;
Clin Infect Dis; 2012 Jun; 54(11):1660-9. PubMed ID: 22474222
[TBL] [Abstract][Full Text] [Related]
11. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
[TBL] [Abstract][Full Text] [Related]
12. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa.
Fox MP; Berhanu R; Steegen K; Firnhaber C; Ive P; Spencer D; Mashamaite S; Sheik S; Jonker I; Howell P; Long L; Evans D
Trop Med Int Health; 2016 Sep; 21(9):1131-7. PubMed ID: 27383454
[TBL] [Abstract][Full Text] [Related]
13. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia.
Aghokeng AF; Monleau M; Eymard-Duvernay S; Dagnra A; Kania D; Ngo-Giang-Huong N; Toni TD; Touré-Kane C; Truong LX; Delaporte E; Chaix ML; Peeters M; Ayouba A;
Clin Infect Dis; 2014 Jan; 58(1):99-109. PubMed ID: 24076968
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study.
Fournier S; Chaffaut C; Maillard A; Loze B; Lascoux C; Gérard L; Timsit J; David F; Bergmann JF; Oksenhendler E; Sereni D; Chevret S; Molina JM
HIV Med; 2005 Mar; 6(2):129-34. PubMed ID: 15807719
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa.
Steegen K; Bronze M; Papathanasopoulos MA; van Zyl G; Goedhals D; Variava E; MacLeod W; Sanne I; Stevens WS; Carmona S
J Antimicrob Chemother; 2017 Jan; 72(1):210-219. PubMed ID: 27659733
[TBL] [Abstract][Full Text] [Related]
16. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.
Røge BT; Barfod TS; Kirk O; Katzenstein TL; Obel N; Nielsen H; Pedersen C; Mathiesen LR; Lundgren JD; Gerstoft J
HIV Med; 2004 Sep; 5(5):344-51. PubMed ID: 15369509
[TBL] [Abstract][Full Text] [Related]
17. Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine.
Bocket L; Yazdanpanah Y; Ajana F; Gerard Y; Viget N; Goffard A; Alcaraz I; Wattré P; Mouton Y
J Antimicrob Chemother; 2004 Jan; 53(1):89-94. PubMed ID: 14645320
[TBL] [Abstract][Full Text] [Related]
18. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.
Boender TS; Hoenderboom BM; Sigaloff KC; Hamers RL; Wellington M; Shamu T; Siwale M; Labib Maksimos EE; Nankya I; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Ondoa P; Rinke de Wit TF
Clin Infect Dis; 2015 Dec; 61(11):1749-58. PubMed ID: 26240203
[TBL] [Abstract][Full Text] [Related]
20. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Stürmer M; Staszewski S; Doerr HW
Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]